4 Years after withdrawal of rofecoxib: Where do we stand today?

Rheumatology International

Volumn 28, Issue 12, 2008, Pages 1187-1195

  Jaksch, W ^a   Dejaco, C ^b   Schirmer, M ^b  

^a Wilhelminenspital der Stadt Wien ^*  (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cardiovascular risk; COX 2 Inhibitors; Gastrointestinal risk; NSAIDs

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; INDOMETACIN; LUMIRACOXIB; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; PIROXICAM; PLACEBO; PROSTACYCLIN; PROSTAGLANDIN SYNTHASE; PROTON PUMP INHIBITOR; ROFECOXIB; THROMBOXANE; VALDECOXIB;

ABDOMINAL PAIN; ARTHRITIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COLORECTAL ADENOMA; COMBINATION CHEMOTHERAPY; DIARRHEA; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG MEGADOSE; DRUG SAFETY; DRUG SCREENING; DYSPEPSIA; ENZYME INHIBITION; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GRAFT REJECTION; HEART PROTECTION; HIP FRACTURE; HUMAN; HYPERKALEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LOW DRUG DOSE; MONOTHERAPY; NAUSEA; PATHOPHYSIOLOGY; PHARMACOEPIDEMIOLOGY; PNEUMONIA; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOSIS; ULCER;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2 INHIBITORS; DRUG AND NARCOTIC CONTROL; DRUG APPROVAL; DRUG THERAPY, COMBINATION; EUROPE; GASTROINTESTINAL HEMORRHAGE; HUMANS; LACTONES; PROTON PUMP INHIBITORS; RHEUMATIC DISEASES; RISK; SULFONES; UNITED STATES;

EID: 51649126930     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-008-0650-4     Document Type: Review

References (71)

1. G Singh G Triadafilopoulos 1999 Epidemiology of NSAID induced gastrointestinal complications J Rheumatol 26 Suppl 56 18 24
2. JR Vane 1971 Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs Nature New Biol 231 232 235
3. DA Kujubu BS Fletcher BC Varnum RW Lim HR Herschman 1991 TIS10 a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells encodes a novel prostaglandin synthase/cyclooxygenase homologue J Biol Chem 266 12866 12872
4. EMEA 2005. Available at: http://www.emea.eu.int/pdfs/human/press/pr/ 6275705en.pdf
5. FDA 2005. Available at: http://www.fda.gov/cder/drug/infopage/COX2/ NSAIDdecisionMemo.pdf
6. MR Tramer RA Moore DJM Reynolds HJ McQuay 2000 Quantitative estimation of rare adverse eventswhich follow a biological progression: a new model applied to chronic NSAID use Pain 85 169 182
7. KC Zimmermann M Sarbia K Schror AA Weber 1998 Constitutive cyclooxygenase-2 expression in healthy human and rabbit gastric mucosa Mol Pharmacol 54 536 540
8. JL Wallace W McKnight BK Reuter N Vergnolle 2000 NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2 Gastroenterology 119 706 714
9. LA García Rodríguez S Hernández-Díaz FJ de Abajo 2001 Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies Br J Clin Pharmacol 52 563 571
10. C Bombardier L Laine A Reicin D Shapiro R Burgos-Vargas B Davis R Day MB Ferraz CJ Hawkey MC Hochberg TK Kvien TJ Schnitzer 2000 Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis NEJM 343 1520 1528
11. FE Silverstein G Faich JL Goldstein LS Simon T Pincus A Whelton R Makuch G Eisen NM Agrawal WF Stenson AM Burr WW Zhao JD Kent JB Lefkowith KM Verburg GS Geis 2000 Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis JAMA 284 1247 1255
12. TJ Schnitzer GR Burmester E Mysler MC Hochberg M Doherty E Ehrsam X Gitton G Krammer B Mellein P Matchaba A Gimona CJ Hawkey 2004 On behalf of the TARGET Study Group comparison of lumiracoxib with naproxen and ibuprofen in the therapeutic arthritis research and gastrointestinal event trial (TARGET) reduction in ulcer complications: randomised controlled trial Lancet 364 9435 675 684
13. MJ Langman DM Jensen DJ Watson SE Harper PL Zhao H Quan JA Bolognese TJ Simon 1999 Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs JAMA 282 1929 1933
14. JL Goldstein FE Silverstein NM Agrawal RC Hubbard J Kaiser CJ Maurath KM Verburg GS Geis 2000 Reduced risk of upper gastrointestinal ulcer complications with celecoxib a novel COX-2 inhibitor Am J Gastroenterol 95 1681 1960
15. JE Edwards HJ McQuay RA Moore 2004 Efficacy and safety of valdecoxib for treatment of osteoarthrosis and rheumatoid arthritis: a systematic review of randomised controlled trials Pain 111 286 296
16. JL Goldstein GM Eisen N Agrawal WF Stenson JD Kent KM Verburg 2004 Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib Aliment Pharmacol Ther 20 527 538
17. GM Eisen JL Goldstein DB Hanna DA Rublee 2005 Meta-analysis: upper gastrointestinal tolerability of valdecoxib, a cyclooxygenase-2-specific inhibitor, compared with nonspecific nonsteroidal anti-inflammatory drugs among patients with osteoarthritis and rheumatoid arthritis Aliment Pharmacol Ther 21 591
18. L Hooper TJ Brown R Elliott K Payne C Roberts D Symmons 2004 The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review BMJ 329 948
19. RA Moore S Derry GT Makinson HJ McQuay 2005 Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from clinical trial reports Arthritis Res Ther 7 R644 R665
20. L Laine SP Curtis B Cryer A Kaur CP Cannon 2007 Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the multinational etoricoxib and diclofenac arthritis long-term (MEDAL) programme: a randomised comparison Lancet 369 465 473
21. E Sheldon A Beaulieu Z Paster D Dutta S Yu VS Sloan 2005 Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week randomized double-blind comparison with celecoxib and placebo Clin Ther 27 1 64 77
22. FKL Chan LCT Hung BY Suen JCY Wu KC Lee VKS Leung AJ Hui KF To WK Leung VWS Wong SCS Chung JJY Sung 2002 Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis NEJM 347 2104 2110
23. RJ Laheij MC Sturkenboom RJ Hassing J Dieleman BH Stricker JB Jansen 2004 Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs JAMA 292 1955 1960
24. S Vakevainen J Tillonen M Salaspuro H Nuutinen H Jousimies-Somer M Farkkila 2000 Hypochlorhydria induced by a proton pump inhibitor leads to intragastric microbial production of acetaldehyde from ethanol Aliment Pharmacol Ther 14 1511 1518
25. Y Yang JD Lewis S Epstein DC Metz 2006 Long-term proton pump inhibitor therapy and risk of hip fracture JAMA 296 2947 2954
26. MC Sturkenboom TA Burke MJ Tangelder JP Dieleman JL Goldstein 2003 Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs Aliment Pharmacol Ther 18 1137 1147
27. G Singh DR Ramey D Morfeld H Shi HT Hatoum JF Fries 1996 Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study Arch Intern 156 14 1530 1536
28. MC Allison AG Howatson CJ Torrance FD Lee RI Russell 1992 Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs N Engl J 327 749 754
29. L Maiden B Thjodleifsson A Theodors J Gonzalez I Bjarnason 2005 A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy Gastroenterology 128 1172 1178
30. JL Goldstein GM Eisen B Lewis IM Gralnek S Zlotnick JG Fort 2005 Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazol, and placebo Clin Gastroenterol Hepatol 3 133 141
31. L Laine LG Connors A Reicin CJ Hawkey R Burgos-Vargas TJ Schnitzer Q Yu C Bombardier 2003 Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use Gastroenterology 124 288 292
32. FKL Chan VWS Wong BY Suen JCY Wu JYL Ching LCT Hung AJ Hui VKS Leung VWY Lee LH Lai GLH Wong DKL Chow KF To WK Leung PWY Chiu YT Lee JYW Lau HLY Chan EKW Ng JJY Sung 2007 Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blindrandomised trial Lancet 369 1611 1626
33. F Wolfe B Freundlich WL Straus 2003 Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis J Rheumatol 30 36 40
34. MM Bertagnolli JE Craig AG Zauber M Redston SD Solomon K Kim J Tang RB Rosenstein J Wittes D Corle TM Hess GM Woloj F Boisserie WF Anderson JL Viner D Bagheri J Burn DC Chung T Dewar R Foley N Hoffmann F Macrae RE Pruitt JR Saltzman B Salzberg T Sylwestrowicz GB Gordon ET Hawk 2006 Celecoxib for the prevention of sporadic colorectal adenomas NEJM 355 9 873 884
35. N Arber JE Craig J Spicak I Racz P Dite J Hajer M Zavoral MJ Lechuga P Gerletti J Tang RB Rosenstein K Macdonald P Bhadra R Fowler J Wittes AG Zauber SD Solomon B Levin 2006 Celecoxib for the prevention of colorectal adenomatous polyps NEJM 355 9 885 895
36. A Lanas R Bresalier R Sandler J Bolognese H Quan B Oxenius K Horgan R Riddell D Morton J Baron 2005 Upper gastrointestinal events associated with rofecoxib in a colorectal adenoma chemoprevention trial Gastroenterology 129 371
37. JL Goldstein AE Bello W Spalding SG Suh JG Fort 2005 Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials J Rheumatol 32 111 117
38. G Singh JG Fort JL Goldstein RA Levy PS Hanrahan AE Bello L Andrade-Ortega C Wallemark NM Agrawal GM Eisen WF Stenson G Triadafilopoulos 2006 Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-1 study Am J Med 119 255 266
39. C Patrono 2006 The PGH-synthase system and isozyme-selective inhibition J Cardiovasc Pharmacol 47 S1 S6
40. C Patrono LA Garcia Rodriguez R Landolfi C Baigent 2005 Low-dose aspirin for the prevention of artherothrombosis NEJM 353 2373 2383
41. F Catella-Lawson MP Reilly SC Kapoor AJ Cucchiara S De-Marco B Tournier SN Vyas GA FitzGerald 2001 Cyclooxygenase inhibitors and the antiplatelet effects of aspirin N Engl J 345 1809 1817
42. G Renda S Tacconelli ML Capone D Sacchetta F Santarelli MG Sciulli M Zimarino M Grana E D'Amelio M Zurro DS Price C Patrono R De Caterina P Patrignani 2006 Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease Clin Pharmacol Ther 800 3 264 274
43. JA Mitchell R Lucas I Vojnovic K Hasan JR Pepper TD Warner 2006 Stronger inhibition by nonsteroid anti-inflammatory drugs of cyclooxygenase-1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events FASEB J 20 2468 2475
44. M Hermann 2006 Cyclooxygenase-2 and nitric oxide J Cardiovasc Pharmacol 47 S21 S25
45. JA Michell TD Warner 2006 COX isoforms in the cardiovascular system: understanding the activities of non-steriodal anti-inflammatory drugs Nature Rev 5 75 85
46. B Hinz H Dormann K Brune 2006 More pronounced inhibition of cyclooxygenase2, increase in blood pressure, and reduction of heart rate by treatment with diclofenac compared with celecoxib and Rofecoxib Arthritis Rheum 54 282 291
47. BF McAdam F Catella-Lawson IA Mardini S Kapoor JA Lawson GA FitzGerald 1999 Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2 Proc Natl Acad Sci 96 272 277
48. CJ Hawkey 1999 COX-2 inhibitors Lancet 353 307 314
49. D Mukherjee SE Nissen EJ Topol 2001 Risk of cardiovascular events associated with selective COX-2 inhibitors JAMA 286 954 959
50. GD Curfman S Morrissey JM Drazen 2005 Expression of concern: bombardier "comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis" N Engl J 2000 343:1520-8 NEJM 353 2813 2814
51. MR Weir RS Spreling A Reicin BJ Gertz 2003 Selective COX-2 inhibition and cardiovascular effects: A review of the rofecoxib development program Am Heart J 146 591 604
52. P Jüni L Nartey S Reichenbach R Sterchi PA Dieppe M Egger 2004 Risk of cardiovascular events and rofecoxib: cumulative meta-analysis Lancet 364 2021 2029
53. RS Bresalier RS Sandler H Quan JA Bolognese B Oxenius K Horgan C Lines R Riddell D Morton A Lanas MA Konstam JA Baron 2005 Cardiovascular events associated with Rofecoxib in a colorectal adenoma chemoprevention trial NEJM 352 1092 1102
54. SE Nissen 2006 Adverse cardiovascular effects of rofecoxib NEJM 355 203 204
55. E Ott NA Nussmeier PC Duke RO Feneck RP Alston MC Snabes RC Hubbard PH Hsu LJ Saidman DT Mangano 2003 Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery J Thorac Cardiovasc Surg 125 1481 1492
56. NA Nussmeier AA Whelton Hoeft MT Brown RM Langford A Hoeft JL Parlow SW Boyce KM Verburg 2005 Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery NEJM 352 1081 1091
57. WB White G Faich A Whelton C Maurath NJ Ridge KM Verburg GS Geis JB Lefkowith 2002 Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac Am J Cardiol 89 425 430
58. ME Farkouh H Kirshner RA Harrington S Ruland FW Verheugt TJ Schnitzer GR Burmester E Mysler MC Hochberg M Doherty E Ehrsam X Gitton G Krammer B Mellein A Gimona P Matchaba CJ Hawkey JH Chesebro 2004 On behalf of the TARGET Study Group comparison of lumiracoxib with naproxen and ibuprofen in the therapeutic arthritis research and gastrointestinal event trial (TARGET), cardiovascular outcomes: randomised controlled trial Lancet 463 675 684
59. PM Kearny C Baigent J Godwin H Emberson JR Halls C Patrono 2006 Do selective cyclo-oxygenase-2 inhibitors and traditional non-steriodal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials BMJ 332 1302 1305
60. P McGettigan D Henry 2006 Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2 JAMA 296 1633 1644
61. Martin BK (ADAPT Research Group). Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's disease anti-inflammatory prevention trial (ADAPT). PLoS Clin Trials 1: e33. doi: 10.1371/journal.pctr. 0010033 http://clinicaltrials.plosjournals.org/perlserv/?request=get- document&doi=10.1371%2Fjournal.pctr.0010033
62. CP Cannon SP Curtis GA FitzGerald H Krum A Kaur JA Bolognese AS Reicin C Bombardier ME Weinblatt D van der Hejde E Erdmann L Laine 2006 Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the multinational etoricoxib and diclofenac arthritis long-term (MEDAL) programme : a randomised comparison Lancet 368 1771 1781
63. RC Harris 2002 Cyclooxygenase-2 inhibition and renal physiology Am J Cardiol 89 10D 17D
64. M Maillard M Burnier 2006 Comperative cardiovascular safety of traditional nonsteroidal anti-inflammatory drugs Expert Opin Drug Saf 5 83 94
65. H Krum TJ Aw D Liew S Haas 2006 Blood pressure effects of COX-2 inhibitors J Cardiovasc Pharmacol 47 S43 S48
66. RC Harris 2006 COX-2 and the kidney J Cardiovasc Pharmacol 47 S37 S42
67. SD Solomon MA Pfeffer JJ McMurray R Fowler P Finn B Levin C Eagle E Hawk M Lechuga AG Zauber MM Bertagnolli N Arber J Wittes 2006 Effects of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas Circulation 114 1028 1035
68. J Zhang EL Ding Jl Song 2006 Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials JAMA 296 1619 1632
69. ME Widlansky DT Price N Gokce RT Eberhardt SJ Duffy M Holbrook C Maxwell J Palmisano JF Keaney JD Morrow JA Vita 2003 Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension Hypertension 42 310 315
70. EMEA 2006. Available at: http://www.emea.europa.eu/pdfs/general/direct/ pr/41313606.pdf
71. T Kurth RJ Glynn AM Walker KA Chan JE Buring CH Hennekens JM Graziano 2003 Inhibition of clinical benefits of aspirinon first myocardial infarction by nonsteroidal antiinflammatory drugs Circulation 108 1191 1195